Sluggish Overseas Sales Growth and Stagnation in North American Fecal Occult Blood Products
First written in FY2017-Q1. 10 of 33 entries say "Reframed", first in FY2017-Q2. Latest entry: 2026-05-12.
The whole theme swung hardest in 2017: 1 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- 2026-05-12AdvancedEarnings
「Overseas revenue continued to increase, driven by higher sales of fecal occult blood testing reagents and medical equipment, reaching ¥11,457 million, up 7.0% year on year.」
Overseas revenue continued its upward trend from the previous period, with growth in fecal occult blood testing reagents and medical equipment. - FY2026-H1AdvancedAnnual report
「Overseas sales were ¥5,449 million, up 11.3% year on year.」
Overseas sales rose 11.3% year on year, indicating a shift from the declining trend seen through the previous fiscal year to a growth trend. - FY2025AdvancedAnnual report
「Overseas sales were ¥10,710 million, up 5.9% year on year, as sales of both urinalysis reagents and fecal occult blood testing reagents grew.」
Overseas sales shifted from the decline in fecal occult blood products in the previous fiscal year to an increase driven by growth in both urine-testing and fecal occult blood-testing products. - FY2025-H1Renewed decline in overseas salesAnnual report
「Overseas sales were ¥4,898 million, up strongly on sales of urinalysis reagents but down 6.4% year on year due to lower sales of fecal occult blood testing reagents.」
Overseas sales fell 6.4% year on year due to a decline in fecal occult blood-testing reagents, compared with the previous recovery phase following the resumption of screening programs in each country. - FY2024-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥7,696 million, up 16.8% year on year.」
The recovery trend has continued, with overseas sales rising 16.8% year on year on higher sales of fecal occult blood-testing reagents, compared with the previous period of sluggish or declining overseas sales. - FY2024-Q2AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥5,233 million, up 18.6% year on year.」
Following the recovery after inventory adjustments through the previous quarter, the increase in fecal occult blood-testing reagents became clear, and overseas sales rose 18.6% year on year. - FY2024-Q1ReframedAnnual report
「Overseas revenue increased as sales of fecal occult blood testing reagents rose following the resolution of the impact of inventory adjustments, despite a decline in sales of urinalysis reagents, reaching ¥2,523 million, up 12.3% year on year.」
The description changed from a decline in overseas sales due to inventory adjustments to a recovery in sales of fecal occult blood-testing reagents as the impact of inventory adjustments subsided, together with higher overseas sales. - FY2023-Q3Decline in overseas sales due to inventory adjustmentsAnnual report
「Overseas revenue increased for urinalysis reagents, but sales of fecal occult blood testing reagents declined because inventories were increased in preparation for the resumption of screening programs and subsequently adjusted, resulting in revenue of ¥6,587 million, down 1.1% year on year.」
Overseas sales fell 1.1% year on year, as the increase in urine-testing reagents was insufficient to offset the decline caused by inventory adjustments for fecal occult blood-testing reagents. - FY2023-Q2RestatedAnnual report
「Overseas revenue increased for urinalysis reagents, but sales of fecal occult blood testing reagents declined, resulting in revenue of ¥4,412 million, down 4.9% year on year.」
After recovering overseas sales continued to decline again, with fecal occult blood testing reagents decreasing despite growth in urine testing reagents. - FY2023-Q1Renewed decline in overseas salesAnnual report
「Overseas revenue increased for urinalysis reagents and analyzers, but sales of fecal occult blood testing reagents and analyzers declined, resulting in revenue of ¥2,246 million, down 4.0% year on year.」
Following the recovery in overseas sales caused by the resumption of screening in individual countries in the previous fiscal year, overseas sales declined 4.0% year on year in the current quarter due to lower sales of fecal occult blood testing products. - FY2022AdvancedAnnual report
「In addition, overseas revenue increased on growth in sales of fecal occult blood testing reagents and analyzers following the resumption of national screening programs, reaching ¥8,868 million, up 28.6% year on year.」
Overseas sales recovered from a period of decline and increased 28.6% year on year, led by fecal occult blood testing products as screening resumed in individual countries. - FY2022-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers following the resumption of national screening programs, reaching ¥6,660 million, up 41.3% year on year.」
With screening programs resuming in individual countries, overseas sales recovered from the interruption and decline seen in the previous fiscal year, increasing 41.3% year on year. - FY2022-Q2AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers following the resumption of national screening programs, reaching ¥4,637 million, up 60.1% year on year.」
The recovery from the decline in overseas sales caused by screening interruptions in the previous fiscal year continued, with overseas sales of fecal occult blood testing reagents and instruments increasing 60.1% year on year. - FY2022-Q1Return to overseas sales growthAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers, reaching ¥2,339 million, up 46.5% year on year.」
The situation changed from declining overseas sales in the previous fiscal year due to interruptions to screening programs in individual countries to 46.5% year-on-year growth in the current quarter, driven by growth in fecal occult blood testing reagents and instruments. - FY2021Overseas sales decline despite recovering demandAnnual report
「Overseas sales were ¥6,895 million, down 2.1% year on year. Sales of genetic testing (LAMP method) reagents and urine testing reagents increased, but sales of fecal occult blood testing reagents and instruments declined for the full year, despite demand showing signs of recovery following the resumption of screening programs in individual countries.」
Although demand for fecal occult blood testing products is recovering as screening resumes, full-year overseas sales were ¥6,895 million, down 2.1% year on year. - FY2021-Q3Decline in overseas sales due to COVID-19Annual report
「Overseas revenue increased for urinalysis reagents and analyzers, but sales of fecal occult blood testing reagents and analyzers declined as participation in national screening programs decreased or programs were suspended, resulting in revenue of ¥4,712 million, down 10.1% year on year.」
The situation has continued to be one of declining overseas sales, as fecal occult blood testing products fell due to lower participation in and interruptions to screening programs in individual countries, reversing the growth trend through the previous fiscal year. - FY2021-Q2Decline in overseas sales due to COVID-19Annual report
「Overseas revenue increased for urinalysis reagents and analyzers, but sales of fecal occult blood testing reagents and analyzers declined as participation in national screening programs decreased or programs were suspended, resulting in revenue of ¥2,897 million, down 17.7% year on year.」
The situation changed from a trend of increasing overseas sales through the previous fiscal year to declining fecal occult blood testing products due to lower participation in and interruptions to screening programs in individual countries, with overseas sales down 17.7% year on year. - FY2021-Q1Decline in overseas sales due to COVID-19Annual report
「Overseas sales were ¥1,596 million, down 11.5% year on year. Sales of urinalysis reagents and equipment increased, but sales of fecal occult blood testing reagents and equipment declined due to lower participation in, and interruptions to, screening programs.」
The situation changed from a trend of increasing overseas sales through the previous fiscal year to declining overseas sales, as fecal occult blood testing reagents and instruments fell due to lower participation in and interruptions to individual screening programs. - FY2020AdvancedAnnual report
「Overseas sales were ¥7,040 million, up 16.0% year on year, as sales of urinalysis reagents and equipment and fecal occult blood testing reagents grew substantially.」
Both fecal occult blood testing and urine testing products and instruments grew, moving from the previous structure of overseas sales led by urine testing products to overseas sales growth driven by higher sales in both product groups. - FY2020-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and urinalysis reagents and analyzers, reaching ¥5,242 million, up 24.6% year on year.」
Both fecal occult blood testing and urine testing products and instruments continued to grow, and overseas sales increased 24.6% year on year to ¥5,242 million. - FY2020-Q2RestatedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and urinalysis reagents and analyzers, reaching ¥3,520 million, up 31.1% year on year.」
The continued description is that both fecal occult blood testing and urine testing products and instruments grew, resulting in higher overseas sales. - FY2020-Q1ReframedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and urinalysis reagents and analyzers, reaching ¥1,803 million, up 35.1% year on year.」
The structure changed from growth in fecal occult blood testing products and declines in overseas urine testing instruments and other products through the previous fiscal year to growth in both fecal occult blood testing and urine testing products and instruments in the current quarter. - FY2019-Q3ReframedAnnual report
「Other products, including medical devices and genetic testing-related products, generated ¥3,135 million, down 11.7% year on year, as increased sales of genetic testing (LAMP method) reagents were offset by lower sales of overseas urine testing instruments and other products. Overseas sales increased 9.6% year on year to ¥4,208 million, driven by substantial growth in sales of fecal occult blood testing reagents.」
The description is that overseas sales are being driven by growth in fecal occult blood testing reagents, while overseas urine testing instruments and other products are declining. - FY2019-Q2ReframedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥2,685 million, up 9.0% year on year.」
The structure changed from growth in both fecal occult blood testing and urine testing products at the end of the previous fiscal year to a structure in which growth in fecal occult blood testing reagents drove overseas sales in the current quarter, while overseas urine testing instruments and other products declined. - FY2019-Q1ReframedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers, reaching ¥1,335 million, up 12.6% year on year.」
The structure changed from growth in both fecal occult blood testing and urine testing products at the end of the previous fiscal year to a structure in which growth in fecal occult blood testing reagents and instruments drove overseas sales in the current quarter, while overseas urine testing instruments declined. - FY2018ReframedAnnual report
「Overseas sales were ¥5,405 million, up 32.3% year on year, as sales of fecal occult blood testing reagents and urinalysis reagents and equipment grew substantially.」
The description changed from a structure of sluggish fecal occult blood testing products and growth in urine testing products to overseas sales growth driven by higher sales in both product groups. - FY2018-Q3RestatedAnnual report
「Overseas sales were ¥3,838 million, up 33.6% year on year, as sales of both fecal occult blood testing reagents and equipment and urinalysis reagents and equipment grew substantially.」
The continued description is that both fecal occult blood testing and urine testing products grew, resulting in overseas sales increasing 33.6% year on year. - FY2018-Q2RestatedAnnual report
「Overseas sales were ¥2,464 million, up 32.3% year on year, as sales of both fecal occult blood testing reagents and equipment and urinalysis reagents and equipment grew substantially.」
The continued description is that both fecal occult blood testing and urine testing products grew, resulting in overseas sales increasing 32.3% year on year. - FY2018-Q1ReframedAnnual report
「Overseas sales were ¥1,185 million, up 65.8% year on year, as sales of both fecal occult blood testing reagents and equipment and urinalysis reagents and equipment grew substantially.」
Rather than the previously described sluggish fecal occult blood testing products, the current quarter is described as having seen a substantial increase in overseas sales driven by growth in both fecal occult blood testing and urine testing products. - FY2017RestatedAnnual report
「As a result, net sales for the fiscal year increased 3.5% year on year to ¥33,274 million, driven by growth in overseas sales and, in Japan, strong growth in rapid testing kits (ImmunoCatch series), as well as fecal occult blood testing reagents, urine test strips and genetic testing (LAMP method) reagents. Overseas sales increased 16.8% year on year to ¥4,086 million, as sales of urine testing reagents and instruments grew despite sluggish sales of fecal occult blood testing reagents.」
For the full year, overseas sales increased, led by urine testing reagents and instruments, while sluggish sales of fecal occult blood testing reagents continued. - FY2017-Q3ReframedAnnual report
「As a result, consolidated net sales for the first 3 quarters increased 4.2% year on year to ¥25,252 million, driven by growth in overseas sales and, in Japan, by core products including fecal occult blood testing reagents, rapid testing kits (ImmunoCatch series) and genetic testing (LAMP method) reagents. Overseas sales increased 16.8% year on year to ¥2,873 million, as sales of urine testing reagents and instruments grew despite sluggish sales of fecal occult blood testing reagents.」
Overall overseas sales turned to 16.8% year-on-year growth, while sluggish sales of fecal occult blood testing reagents continued and urine testing reagents and instruments drove the increase. - FY2017-Q2ReframedAnnual report
「Overseas sales were ¥1,862 million, up 6.0% year on year, as growth in urinalysis reagents and equipment outweighed sluggish sales of fecal occult blood testing reagents and equipment.」
The description has shifted from overall sluggish overseas sales to a structure in which stagnant fecal occult blood testing products coexist with growth in urine testing products. - FY2017-Q1First statedAnnual report
「Although overseas sales remained sluggish, domestic sales of core products, including fecal occult blood testing reagents and rapid testing reagents, increased significantly, reaching ¥8,254 million, up 5.4% year on year.」
Overall overseas sales remained sluggish, while North American sales of fecal occult blood testing reagents were ¥715 million, down 0.3% year on year.